Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-003 Delivered by Intravenous Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Zaawansowany nowotwór stały, potwierdzony badaniem histologicznym lub cytologicznym
- •Co najmniej jeden wymierny guz do zmierzenia
- •Brak możliwości wyleczenia tradycyjnymi metodami lub brak skuteczności dotychczasowego leczenia
- •Ogólny stan zdrowia pozwalający na uczestnictwo (ECOG 0-1)
- •Szacowana długość życia co najmniej 12 tygodni
- •Waga co najmniej 40 kg
- •Wystarczająco dobre funkcjonowanie nerek, wątroby i krwi
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
HonorHealth Research Institute
Scottsdale, United States
Sarah Cannon Research Institute
Nashville, United States
Trial contact
Jason Luke, MD, Chief Medical Officer
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.